1. Home
  2. AKRO vs RNW Comparison

AKRO vs RNW Comparison

Compare AKRO & RNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • RNW
  • Stock Information
  • Founded
  • AKRO 2017
  • RNW 2011
  • Country
  • AKRO United States
  • RNW United Kingdom
  • Employees
  • AKRO N/A
  • RNW N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • RNW Electric Utilities: Central
  • Sector
  • AKRO Health Care
  • RNW Utilities
  • Exchange
  • AKRO Nasdaq
  • RNW Nasdaq
  • Market Cap
  • AKRO 2.2B
  • RNW 2.6B
  • IPO Year
  • AKRO 2019
  • RNW N/A
  • Fundamental
  • Price
  • AKRO $29.53
  • RNW $7.03
  • Analyst Decision
  • AKRO Strong Buy
  • RNW Strong Buy
  • Analyst Count
  • AKRO 8
  • RNW 3
  • Target Price
  • AKRO $46.83
  • RNW $8.67
  • AVG Volume (30 Days)
  • AKRO 535.2K
  • RNW 1.4M
  • Earning Date
  • AKRO 11-08-2024
  • RNW 11-19-2024
  • Dividend Yield
  • AKRO N/A
  • RNW N/A
  • EPS Growth
  • AKRO N/A
  • RNW N/A
  • EPS
  • AKRO N/A
  • RNW 0.05
  • Revenue
  • AKRO N/A
  • RNW $998,525,966.00
  • Revenue This Year
  • AKRO N/A
  • RNW N/A
  • Revenue Next Year
  • AKRO N/A
  • RNW $28.21
  • P/E Ratio
  • AKRO N/A
  • RNW $129.65
  • Revenue Growth
  • AKRO N/A
  • RNW N/A
  • 52 Week Low
  • AKRO $15.32
  • RNW $5.15
  • 52 Week High
  • AKRO $37.00
  • RNW $7.79
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 46.87
  • RNW 69.97
  • Support Level
  • AKRO $28.45
  • RNW $6.99
  • Resistance Level
  • AKRO $31.41
  • RNW $7.49
  • Average True Range (ATR)
  • AKRO 1.29
  • RNW 0.27
  • MACD
  • AKRO -0.15
  • RNW 0.10
  • Stochastic Oscillator
  • AKRO 37.64
  • RNW 77.17

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About RNW ReNew Energy Global plc

ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.

Share on Social Networks: